[go: up one dir, main page]

GB201313249D0 - Method - Google Patents

Method

Info

Publication number
GB201313249D0
GB201313249D0 GBGB1313249.3A GB201313249A GB201313249D0 GB 201313249 D0 GB201313249 D0 GB 201313249D0 GB 201313249 A GB201313249 A GB 201313249A GB 201313249 D0 GB201313249 D0 GB 201313249D0
Authority
GB
United Kingdom
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1313249.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GBGB1313249.3A priority Critical patent/GB201313249D0/en
Publication of GB201313249D0 publication Critical patent/GB201313249D0/en
Priority to PCT/GB2014/051874 priority patent/WO2014202978A1/en
Priority to EP14732605.2A priority patent/EP3011008B1/en
Priority to US14/899,523 priority patent/US10877033B2/en
Priority to PCT/GB2014/052264 priority patent/WO2015011478A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GBGB1313249.3A 2013-06-18 2013-07-25 Method Ceased GB201313249D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB1313249.3A GB201313249D0 (en) 2013-07-25 2013-07-25 Method
PCT/GB2014/051874 WO2014202978A1 (en) 2013-06-18 2014-06-18 Method of detecting the presence or absence of autoantibodies
EP14732605.2A EP3011008B1 (en) 2013-06-18 2014-06-18 Method of detecting the presence or absence of autoantibodies
US14/899,523 US10877033B2 (en) 2013-06-18 2014-06-18 Method of detecting the presence or absence of autoantibodies
PCT/GB2014/052264 WO2015011478A1 (en) 2013-07-25 2014-07-24 Method of producing a preparation of membrane vesicles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1313249.3A GB201313249D0 (en) 2013-07-25 2013-07-25 Method

Publications (1)

Publication Number Publication Date
GB201313249D0 true GB201313249D0 (en) 2013-09-11

Family

ID=49166887

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1313249.3A Ceased GB201313249D0 (en) 2013-06-18 2013-07-25 Method

Country Status (2)

Country Link
GB (1) GB201313249D0 (en)
WO (1) WO2015011478A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
KR102761577B1 (en) 2017-05-08 2025-02-03 플래그쉽 파이어니어링 이노베이션스 브이, 인크. Composition for promoting membrane fusion and its use
JP7520717B2 (en) * 2018-02-17 2024-07-23 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド Compositions and methods for membrane protein delivery - Patents.com
MX2021000308A (en) 2018-07-09 2021-06-08 Flagship Pioneering Innovations V Inc FUSOSOME COMPOSITIONS AND THEIR USES.
KR20210131991A (en) 2018-11-14 2021-11-03 플래그쉽 파이어니어링 이노베이션스 브이, 인크. Compositions and methods for compartment-specific cargo delivery
EP4225360A1 (en) 2020-10-08 2023-08-16 Virothera Limited Vaccine compositions
AU2022253020A1 (en) 2021-04-08 2023-10-26 Sana Biotechnology, Inc. Cd8-specific antibody constructs and compositions thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103171D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
IL160142A0 (en) * 2001-08-17 2004-06-20 Anosys Inc Methods and compounds for the targeting of protein to exosomes
US20030148454A1 (en) * 2001-11-02 2003-08-07 Trustees Of Boston University Virus-free vesicles for delivery of functional membrane bound proteins
JP5878126B2 (en) * 2009-11-13 2016-03-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Direct protein delivery using engineered microvesicles

Also Published As

Publication number Publication date
WO2015011478A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
GB201314695D0 (en) Method
GB201318465D0 (en) Method
GB201320351D0 (en) Method
GB201309057D0 (en) Method
GB201316744D0 (en) Method
GB201316849D0 (en) Method
GB201309928D0 (en) Method
GB201313249D0 (en) Method
GB201301857D0 (en) Method
GB201300409D0 (en) Method
GB201309654D0 (en) Method
GB201305714D0 (en) Method
GB201301233D0 (en) Method
GB201311385D0 (en) Method
GB201301094D0 (en) Method
GB201312609D0 (en) Method
GB201318490D0 (en) Method
GB201314054D0 (en) Method
GB201311389D0 (en) Method
GB201322768D0 (en) Method
GB201320660D0 (en) Method
GB201319361D0 (en) Method
GB201318830D0 (en) Method
GB201317970D0 (en) Method
GB201317826D0 (en) Method

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)